{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054478","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.974480+00:00","generated_at":"2026-06-02T18:17:26.532367+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi Therapeutics Q1 2024 net loss $10.9M; cash $72.8M; clinical trials on track","bullets":["Net loss of $10.9M vs $6.4M in Q1 2023; R&D expense rose to $8.8M from $5.0M.","Cash, equivalents and marketable securities $72.8M; runway expected into 2026.","Phase 2a RIVER trial in RCC fully enrolled? all sites activated; topline data expected H2 2024.","Phase 2b CORAL trial in IPF chronic cough enrolling ~160 pts; topline data H1 2025.","HAP study 75% enrolled; IND cleared for Phase 1b respiratory physiology trial starting Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054478","json":"https://secwatch.observer/filing/0000950170-24-054478.json","markdown":"https://secwatch.observer/filing/0000950170-24-054478.md","text":"https://secwatch.observer/filing/0000950170-24-054478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024054478/0000950170-24-054478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024054478/trvi-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:17:26.532367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0fbefbe7248ace71ee2d5bd61d051083d9fa5e9","claim":"Trevi Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.. Guidance reaffirmed.","evidence_excerpt":"Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.4 million in the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024054478/0000950170-24-054478-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6."},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}